BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MacroGenics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MacroGenics's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06730347-10812@assetmemo.bio
DTSTAMP:20261121T005340Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lorigerlimab: Phase 2 readout est. (NCT06730347)
DESCRIPTION:Lorigerlimab\, phase 2.\nStudy: A Study of Lorigerlimab in Part
 icipants With Advanced Solid Tumors\nEstimated primary completion: July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lorigerlimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06730347
URL:https://assetmemo.bio/drug/lorigerlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
